3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Lymphoid
5
Myeloid
4
Other solid neoplasm
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
78
Fulvestrant
76
Carboplatin
74
Trastuzumab
71
Capecitabine
69
Letrozole
62
Cyclophosphamide
61
Paclitaxel
60
pertuzumab
52
Specimen Handling
52
Docetaxel
50
abemaciclib
46
ribociclib
44
Anastrozole
35
130-nm albumin-bound paclitaxel
35
trastuzumab deruxtecan
34
Magnetic Resonance Spectroscopy
33
Blood Specimen Collection
33
Tamoxifen
32
sacituzumab govitecan
31
exemestane
31
Biopsy
31
Gemcitabine
30
Epirubicin
29
pyrotinib
28
palbociclib
28
Surveys and Questionnaires
27
Injections
27
Drug Therapy
27
eribulin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Blood Component Removal
×
Breast
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled